NASDAQ:ESLA Estrella Immunopharma (ESLA) Stock Price, News & Analysis $1.26 -0.01 (-0.79%) As of 12:08 PM Eastern This is a fair market value price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Estrella Immunopharma Stock (NASDAQ:ESLA) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Estrella Immunopharma alerts:Sign Up Key Stats Today's Range$1.21▼$1.2750-Day Range$0.97▼$1.9252-Week Range$0.78▼$3.15Volume13,491 shsAverage Volume163,804 shsMarket Capitalization$53.76 millionP/E RatioN/ADividend YieldN/APrice Target$8.00Consensus RatingHold Company Overview Estrella Immunopharma, Inc., a preclinical-stage biopharmaceutical company, develops T-cell therapies for blood cancers and solid tumors in the United States. The company's lead product candidates include EB103 for the treatment of diffuse large B-cell lymphoma and is in pre clinical trial; and EB104 to treat diffuse large B-cell lymphoma and acute lymphocytic leukemia. It has a collaborative partnership with Imugene Limited for the development of solid tumor treatments using Imugene's product candidate CF33-CD19t in conjunction with EB103. Estrella Immunopharma, Inc. is based in EmeryVille, California. Read More Estrella Immunopharma Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks45th Percentile Overall ScoreESLA MarketRank™: Estrella Immunopharma scored higher than 45% of companies evaluated by MarketBeat, and ranked 488th out of 860 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.4 / 5Analyst RatingHold Consensus RatingEstrella Immunopharma has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on no strong buy ratings, 1 buy rating, no hold ratings, and 1 sell rating.Upside PotentialEstrella Immunopharma has a consensus price target of $8.00, representing about 534.9% upside from its current price of $1.26.Amount of Analyst CoverageEstrella Immunopharma has only been the subject of 2 research reports in the past 90 days.Read more about Estrella Immunopharma's stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Estrella Immunopharma are expected to grow in the coming year, from ($0.39) to ($0.32) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Estrella Immunopharma is -3.60, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Estrella Immunopharma is -3.60, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Read more about Estrella Immunopharma's valuation and earnings. Short Interest5.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted1.39% of the float of Estrella Immunopharma has been sold short.Short Interest Ratio / Days to CoverEstrella Immunopharma has a short interest ratio ("days to cover") of 0.88, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Estrella Immunopharma has recently decreased by 57.56%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldEstrella Immunopharma does not currently pay a dividend.Dividend GrowthEstrella Immunopharma does not have a long track record of dividend growth. News and Social Media0.0 / 5News Sentiment0.00 News Coverage This WeekMarketBeat has tracked 2 news articles for Estrella Immunopharma this week, compared to 1 article on an average week. Company Ownership0.7 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Estrella Immunopharma insiders have not sold or bought any company stock.Percentage Held by Insiders55.10% of the stock of Estrella Immunopharma is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions0.35% of the stock of Estrella Immunopharma is held by institutions.Read more about Estrella Immunopharma's insider trading history. Receive ESLA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Estrella Immunopharma and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. ESLA Stock News HeadlinesEstrella Immunopharma to Participate in the D. Boral Capital Global ConferenceMay 5 at 8:00 AM | businesswire.comEstrella Immunopharma, Inc. (NASDAQ: ESLA) Receives Initiating Coverage with a Valuation of $12.00/Share from Zacks Small-Cap ResearchMarch 23, 2026 | finance.yahoo.comThe AI stocks about to become worthless (and one that isn't)Louis Navellier - who manages $1.1 billion including $358 million in AI stocks - says a new AI computer being built at a classified government facility in Tennessee could make today's leading AI models obsolete overnight. He compares it to the iPhone moment that wiped out Nokia, BlackBerry, and Motorola. When this machine comes online, it will reportedly accelerate AI breakthroughs 360-fold - compressing five years of progress into five days. Navellier has identified specific stocks he'd sell before this hits, and one ticker he'd buy before May 5th.May 8 at 1:00 AM | InvestorPlace (Ad)ESLA: 100% CR Rate in Phase 1/2 Trial of EB103 in Aggressive B Cell NHLFebruary 10, 2026 | msn.comEstrella Immunopharma (ESLA) price target decreased by 50.00% to 8.16February 4, 2026 | msn.comEstrella Immunopharma Announces Late-Breaking Oral Presentation of Phase 1 STARLIGHT-1 Data for EB103 at the 2026 Tandem Meetings of ASTCT® & CIBMTR®February 3, 2026 | finance.yahoo.comEstrella Immunopharma Receives Nasdaq Non-Compliance NoticeJanuary 15, 2026 | theglobeandmail.comEstrella Immunopharma Announces Closing of $8.0 Million Registered Direct Offering and Concurrent Private PlacementJanuary 6, 2026 | businesswire.comSee More Headlines ESLA Stock Analysis - Frequently Asked Questions How have ESLA shares performed this year? Estrella Immunopharma's stock was trading at $1.56 at the beginning of 2026. Since then, ESLA shares have decreased by 19.2% and is now trading at $1.26. How were Estrella Immunopharma's earnings last quarter? Estrella Immunopharma, Inc. (NASDAQ:ESLA) announced its quarterly earnings results on Wednesday, March, 18th. The company reported ($0.01) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.18) by $0.17. How do I buy shares of Estrella Immunopharma? Shares of ESLA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Estrella Immunopharma own? Based on aggregate information from My MarketBeat watchlists, some other companies that Estrella Immunopharma investors own include NuCana (NCNA), Cardio Diagnostics (CDIO), Caribou Biosciences (CRBU), GRI Bio (GRI), Intrusion (INTZ), Children's Place (PLCE). Company Calendar Last Earnings3/18/2026Today5/08/2026Next Earnings (Estimated)5/13/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Yellow Zone (4d) 1-Year History May 25 Aug 25 Nov 25 Feb 26 May 26 As of 4 days ago, ESLA's financial health entered the Yellow zone, according to TradeSmith. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - BIOMED/GENE Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:ESLA CIK1844417 Webwww.estrellabio.com Phone510-318-9098FaxN/AEmployeesN/AYear FoundedN/APrice Target and Rating Average Price Target for Estrella Immunopharma$8.00 High Price Target$8.00 Low Price Target$8.00 Potential Upside/Downside+534.9%Consensus RatingHold Rating Score (0-4)2.00 Research Coverage2 Analysts Profitability EPS (Trailing Twelve Months)($0.35) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$13.06 million Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on Assets-430.91% Debt Debt-to-Equity RatioN/A Current Ratio0.12 Quick Ratio0.12 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value($0.27) per share Price / Book-4.67Miscellaneous Outstanding Shares42,665,000Free Float19,157,000Market Cap$53.76 million OptionableNot Optionable Beta0.97 7 Stocks That Will Be Magnificent in 2026Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2026. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.Get This Free Report This page (NASDAQ:ESLA) was last updated on 5/8/2026 by MarketBeat.com Staff. From Our PartnersYour book attachedYour Download Link (Expiring) If you still haven't downloaded the free Simple Options Trading For Beginners...Profits Run | SponsoredIran's New Leader Just Said Something That Should Terrify Every AmericanIran's Supreme Leader has declared the Strait of Hormuz closed as leverage against the U.S. - and with 40% of ...American Alternative | SponsoredOne executive order. The biggest wealth transfer of your lifetime.On August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...Reagan Gold Group | SponsoredSpaceX eyes a 1.75 trillion valuation - here's what to knowElon Musk's team has quietly filed confidential paperwork with the SEC for what Bloomberg estimates could be a...Brownstone Research | SponsoredThe Death of the Nasdaq?The Death of the Nasdaq? Wall Street legend Marc Chaikin's award-winning system turned bearish on software ...Chaikin Analytics | SponsoredBefore you buy SpaceX shares, consider this alternative approachSpaceX has confidentially filed for an IPO with the SEC, targeting a June 2026 listing at a valuation exceedin...Weiss Ratings | Sponsored‘Please’: OpenAI CEO Sam Altman Begs Small Company for HelpSpaceX 'Dark Energy' Replaces Foreign Oil For years, we've been told SpaceX is a rocket company. But accord...Altimetry | SponsoredIs the SpaceX IPO “Rigged?”The SpaceX IPO filing is official, with 21 banks - including JPMorgan, Goldman Sachs, and Morgan Stanley - pre...The Oxford Club | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Estrella Immunopharma, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Estrella Immunopharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free ESLA Stock Alerts